Expedition Therapeutics

Developer of treatments targeting inflammatory and respiratory diseases for patient care. The company focuses on treatments addressing fundamental disease mechanisms for chronic obstructive pulmonary disease. Their therapy targets neutrophilic inflammation, a pathway driving tissue damage and lung function decline. The lead candidate is an oral DPP1 inhibitor being developed for COPD. It aims to deliver improvement for patients lacking disease-controlling options.